Mini-reviewTargeting EGFRvIII for glioblastoma multiforme

- Targeting EGFRvIII using CAR T-cell therapy.
- The role of EGFRvIII specific therapeutic vaccine in GBM.
- Preclinical and clinical findings of antibodies against EGFRvIII for treating GBM.
- Preclinical findings of Bi-specific T-Cell Engager targeting EGFRvIII for GBM.

Glioblastoma multiforme (GBM) is the most progressive primary brain tumor. Targeting a novel and highly specific tumor antigen is one of the strategies to overcome tumors. EGFR variant III (EGFRvIII) is present in 25%-33% of all patients with GBM and is exclusively expressed on tumor tissue cells. Currently, there are various approaches to target EGFRvIII, including CAR T-cell therapy, therapeutic vaccines, antibodies, and Bi-specific T Cell Engager. In this review, we focus on the preclinical and clinical findings of targeting EGFRvIII for GBM.